Astellas Venture Management

Type

Venture Capital

Status

Active

Location

San Francisco, United States

Total investments

65

Average round size

24M

Portfolio companies

44

Rounds per year

3.42

Lead investments

4

Follow on index

0.31

Exits

10

Stages of investment
Private EquityEarly Stage VentureLate Stage Venture
Areas of investment
BiotechnologyHealth CareGeneticsMedical DeviceMedicalLife SciencePharmaceuticalTherapeuticsBiopharmaSimulation

Summary

Astellas Venture Management is the famous Corporate Investor, which was founded in 2005. The company was established in North America in United States. The main office of represented Corporate Investor is situated in the Menlo Park.

The typical case for the fund is to invest in rounds with 5-6 participants. Despite the Astellas Venture Management, startups are often financed by MPM Capital, U.S. Venture Partners (USVP), SR One. The meaningful sponsors for the fund in investment in the same round are MPM Capital, U.S. Venture Partners (USVP), SR One. In the next rounds fund is usually obtained by Novartis Venture Fund, SR One, MPM Capital.

The real fund results show that this Corporate Investor is 6 percentage points less often commits exit comparing to other companies. The increased amount of exits for fund were in 2018. The common things for fund are deals in the range of 10 - 50 millions dollars. The fund is constantly included in 2-6 investment rounds annually. Opposing the other organizations, this Astellas Venture Management works on 4 percentage points less the average amount of lead investments. The important activity for fund was in 2014. Despite it in 2019 the fund had an activity.

The fund has no specific favorite in a number of founders of portfolio startups. When startup sums 4 or 5+ of the founder, the probability for it to get the investment is little. Moreover, a startup needs to be at the age of 4-5 years to get the investment from the fund. Among the most popular fund investment industries, there are Medical Device, Food and Beverage. For fund there is a match between the location of its establishment and the land of its numerous investments - United States. Among the most popular portfolio startups of the fund, we may highlight F2G, Twentyeight-Seven Therapeutics, Tizona Therapeutics.

Show more

Investor highlights

Industry focus
Biotech/Life SciencesMedtech
Stage focus
Seed

Discover reliable insights

Find relevant VC investors, identify key contacts and secure funding opportunities.

Investments analytics

Analytics

Total investments
65
Lead investments
4
Exits
10
Rounds per year
3.42
Follow on index
0.31
Investments by industry
  • Biotechnology (57)
  • Health Care (37)
  • Therapeutics (31)
  • Medical (19)
  • Pharmaceutical (14)
  • Show 20 more
Investments by region
  • United States (41)
  • United Kingdom (15)
  • Japan (5)
  • Switzerland (1)
  • Canada (1)
Peak activity year
2020
Number of Unicorns
1
Number of Decacorns
1
Number of Minotaurs
2

Discover reliable insights

Leverage validated data, identify key contacts and secure funding opportunities for your business.

Quantitative data

Avg. startup age at the time of investment
10
Avg. valuation at time of investment
36M
Group Appearance index
0.91
Avg. company exit year
10
Strategy success index
0.70

Need more data?

Get access to full data about investors, including their team, contact information, and historic data.

Latest deals

Company name Deal date Industry Deal stage Deal size Location
NeoPhore 01 Feb 2024 Biotechnology, Therapeutics, Simulation, Translation Service Early Stage Venture 13M England, Cambridge, United Kingdom
Verastem Oncology 14 Jul 2011 Biotechnology, Pharmaceutical, Biopharma Early Stage Venture 32M United States, Massachusetts

Similar funds

By same location

By same geo focus

By doing lead investments

How we get our data

At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).

Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.